- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07570316
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease (VitaliThy)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.
The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.
The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.
More information can be found here: https://clinicaltrials.argenx.com/vitalithy
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Sabine Coppieters, MD
- Telefonnummer: 857-350-4834
- E-mail: clinicaltrials@argenx.com
Studiesteder
-
-
Tyne and Wear
-
Gateshead, Tyne and Wear, Det Forenede Kongerige, NE9 6SX
- Rekruttering
- Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)
-
Kontakt:
- Syed Salman Razvi
- Telefonnummer: +44 191 445 6052
- E-mail: salman.razvi@newcastle.ac.uk
-
-
-
-
California
-
Carlsbad, California, Forenede Stater, 92012
- Rekruttering
- Profound Research LLC at Tri-City Primary Care
-
Kontakt:
- Jamil Alkhaddo, MD
- Telefonnummer: 419-681-0637
- E-mail: jamil.alkhaddo@profoundresearch.com
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- Diabetes Associates Medical Group
-
Kontakt:
- Ivy-Joan Madu, MD
- Telefonnummer: 714-202-8894
- E-mail: diabetesmd@sbcglobal.net
-
Pasadena, California, Forenede Stater, 91101
- Rekruttering
- Pasadena Clinical Trials
-
Kontakt:
- Tzu-Jen Tzao
- Telefonnummer: 5206127860
- E-mail: ttzao@pasadenatrials.com
-
Pasadena, California, Forenede Stater, 91105
- Rekruttering
- Havana Research Institute LLC.
-
Kontakt:
- John De Beixedon, MD
- Telefonnummer: 626-698-9794
- E-mail: drjohn@havanaresearchinstitute.com
-
San Jose, California, Forenede Stater, 95128
- Rekruttering
- San Jose Clinical Trials
-
Kontakt:
- Richard Cherlin
- Telefonnummer: 408-358-2663
- E-mail: rcherlin@sanjosetrials.com
-
-
Florida
-
Fleming Island, Florida, Forenede Stater, 32003
- Rekruttering
- Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location
-
Kontakt:
- Senan Sultan, MD
- Telefonnummer: 478-319-7900
- E-mail: drsultan@nerifl.com
-
Fort Lauderdale, Florida, Forenede Stater, 33312
- Rekruttering
- The Center for Diabetes and Endocrine Care
-
Kontakt:
- Sam Lerman, MD
- Telefonnummer: 954-963-7100
- E-mail: slerman@diabetes-endocare.com
-
Jacksonville, Florida, Forenede Stater, 32256
- Rekruttering
- University of Florida Jacksonville College of Medicine
-
Kontakt:
- Christian Koch
- Telefonnummer: +1 857-350-4834
- E-mail: Christian.Koch@jax.ufl.edu
-
Kissimmee, Florida, Forenede Stater, 34744
- Rekruttering
- Ilumina Medical Research LLC
-
Kontakt:
- Max Sosa-Pagan, MD
- Telefonnummer: 857-350-4834
- E-mail: MSosapaganMD@gmail.com
-
Miami, Florida, Forenede Stater, 33144
- Rekruttering
- Oceane 7 Medical & Research Center, Inc
-
Kontakt:
- Orlando Fernandez
- Telefonnummer: 305 261 2738
- E-mail: o.fernandez.oceane7@gmail.com
-
-
Kansas
-
Lenexa, Kansas, Forenede Stater, 66219
- Rekruttering
- Johnson County Clin-Trials, Inc.
-
Kontakt:
- Thomas Kreamer, MD
- Telefonnummer: 913-825-4400
- E-mail: tkreamer@jcct.com
-
Wichita, Kansas, Forenede Stater, 67226
- Rekruttering
- Alliance for Multispecialty Research, LLC
-
Kontakt:
- Terry Klein
- Telefonnummer: 316-689-6629
- E-mail: terry.klein@amr-clinical.com
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan
-
Kontakt:
- Tae-Hwa Chun
- Telefonnummer: 734-615-5420
- E-mail: taehwa@med.umich.edu
-
Dearborn, Michigan, Forenede Stater, 48126
- Rekruttering
- Metro Detroit Endocrinology Center
-
Kontakt:
- Ayman Elkadry, MD
- Telefonnummer: 313-203-5300
- E-mail: aymankad73@gmail.com
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Rekruttering
- Profound Research
-
Kontakt:
- Gary Edelson, MD
- Telefonnummer: 947-254-1920
- E-mail: gary.edelson@profoundresearch.io
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64108
- Rekruttering
- Truman Medical Center
-
Kontakt:
- Rajib Bhattacharya, MD
- Telefonnummer: +1 857-350-4834
- E-mail: rajib.bhattacharya@uhkc.org
-
-
New York
-
Albany, New York, Forenede Stater, 12203
- Rekruttering
- Albany Medical College Community Endocrinology
-
Kontakt:
- Robert Busch
- Telefonnummer: 518 489 4704
- E-mail: thyroiddoc@aol.com
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Endocrine Associates of West Village PC
-
Kontakt:
- Anastasios Manessis, MD
- Telefonnummer: 646-660-9991
- E-mail: amanessis@endocrinenyc.com
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28803
- Rekruttering
- Asheville Clinical Research
-
Kontakt:
- Lauren Bernstein
- Telefonnummer: +1 857-350-4834
- E-mail: bbernstein@ashevilleclinicaltrials.com
-
Raleigh, North Carolina, Forenede Stater, 27612
- Rekruttering
- Wake Internal Medicine Consultants
-
Kontakt:
- Juman Takeddin, MD
- Telefonnummer: 919-781-7500
- E-mail: jtakeddin@wakeinternalmedicine.com
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231
- Rekruttering
- Research Institute of Dallas
-
Kontakt:
- Heidi Shea, MD
- Telefonnummer: 927-867-4658
- E-mail: hshea@eadallas.com
-
El Paso, Texas, Forenede Stater, 79935
- Rekruttering
- Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine
-
Kontakt:
- Sergio Rovner
- Telefonnummer: 915-633-9387
- E-mail: sergiorovner@hotmail.com
-
Houston, Texas, Forenede Stater, 77040
- Rekruttering
- Juno Research
-
Kontakt:
- Damaris Vega, MD
- Telefonnummer: 713-779-5494
- E-mail: Dvega@jcct.com
-
Houston, Texas, Forenede Stater, 77089
- Rekruttering
- Clinic of Endocrinology
-
Kontakt:
- Amir Hassan, MD
- Telefonnummer: 281-944-3610
- E-mail: amir@biopharmainfo.net
-
Irving, Texas, Forenede Stater, 75039
- Rekruttering
- Tekton Research Irving
-
Kontakt:
- Pablo Mora, MD
- Telefonnummer: 972-566-7799
- E-mail: pablo.mora@tektonresearch.com
-
McAllen, Texas, Forenede Stater, 78503
- Rekruttering
- Biopharma Informatic, LLC
-
Kontakt:
- Gloria Ortiz, MD
- Telefonnummer: 281-944-3610
- E-mail: gortiz@biopharmainfo.net
-
McKinney, Texas, Forenede Stater, 75069
- Rekruttering
- Tekton Research - McKinney
-
Kontakt:
- Muhammad Siddiqui, MD
- Telefonnummer: 972-777-6011
- E-mail: muhammad.siddiqui@tektonresearch.com
-
Mesquite, Texas, Forenede Stater, 75149
- Rekruttering
- Southern Endocrinology Associates PA
-
Kontakt:
- Sumana Gangi, MD
- Telefonnummer: 214-909-8904
- E-mail: sumana_gangi@yahoo.com
-
Shavano Park, Texas, Forenede Stater, 78231
- Rekruttering
- Consano Clinical Research
-
Kontakt:
- Daniel Katselnik, MD
- Telefonnummer: 210-545-4900
- E-mail: katselnik.md@consanosa.com
-
-
-
-
-
Tbilisi, Georgien, 0114
- Rekruttering
- New Hospitals
-
Kontakt:
- Lia Katcharava, MD
- Telefonnummer: +995 599530278
- E-mail: likakatcharava@yahoo.com
-
Tbilisi, Georgien, 0102
- Rekruttering
- LLC American Hospital Network
-
Kontakt:
- Nino Gabidzashvili, MD
- E-mail: endo.advice@gmail.com
-
Tbilisi, Georgien, 0119
- Rekruttering
- LLC Todua Clinic
-
Kontakt:
- Tamar Khutsishvili, MD
- E-mail: Khutsishvilitamar1@outlook.com
-
Tbilisi, Georgien, 0112
- Rekruttering
- LTD Israeli-Georgian Medical Research Clinic Healthycore
-
Kontakt:
- Miranda Baratashvili, MD
- E-mail: baratashvilimiranda@gmail.com
-
Tbilisi, Georgien, 0159
- Rekruttering
- In Vitro Fertilization Center LLC
-
Kontakt:
- Tea Khurodze, MD
- E-mail: khurodze@yahoo.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
- Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening.
- Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
- Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.
Exclusion Criteria:
- History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).
- History of RAI (radioactive iodine) therapy or received a total thyroidectomy.
- T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening.
- Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.
- Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part A - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Placebo komparator: Part A - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Eksperimentel: Part B - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Eksperimentel: Part B - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Eksperimentel: Part C - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
Free triiodothyronine: [fT3]; free thyroxine: [fT4]; ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to becoming euthyroid
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
Up to 24 weeks (part A) + up to 135 weeks
|
|
|
Efgartigimod serum concentrations over time
Tidsramme: Up to 24 weeks (part A) + 72 weeks (part C)
|
Up to 24 weeks (part A) + 72 weeks (part C)
|
|
|
Time to becoming euthyroid off ATDs in part A
Tidsramme: Up to 24 weeks (part A)
|
ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (part A)
|
|
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
ULN : upper limit of normal; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Time to becoming euthyroid off ATDs and TRAb seronegative
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies. |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Tidsramme: Up to 24 weeks (Part A)
|
ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (Part A)
|
|
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Tidsramme: Up to 24 weeks (part A)
|
TSH: thyroid-stimulating hormone; LLN: lower limit of normal. |
Up to 24 weeks (part A)
|
|
Percentage of participants who remain euthyroid without ATDs
Tidsramme: Up to 74 weeks (part B)
|
ATDs: antithyroid drug |
Up to 74 weeks (part B)
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Tidsramme: Up to 74 weeks (part B) + up to 135 weeks
|
ATDs: antithyroid drug |
Up to 74 weeks (part B) + up to 135 weeks
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Tidsramme: Up to 72 weeks (part C)
|
ATDs: antithyroid drug |
Up to 72 weeks (part C)
|
|
Incidence of AEs and SAEs
Tidsramme: Up to 135 weeks
|
AEs: adverse events ; SAEs: serious adverse events. |
Up to 135 weeks
|
|
Change in ThyPRO-39 over time
Tidsramme: Up to 135 weeks
|
The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status. |
Up to 135 weeks
|
|
Change in PROMIS-PF10a over time
Tidsramme: Up to 135 weeks
|
The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function. |
Up to 135 weeks
|
|
Percentage change from baseline in total IgG levels in serum over time
Tidsramme: Up to 98 weeks
|
IgG: immunoglobulin G |
Up to 98 weeks
|
|
Percentage change from baseline in TRAb serum levels over time
Tidsramme: Up to 135 weeks
|
TRAb: anti-TSHR autoantibodies. |
Up to 135 weeks
|
|
Incidence of ADA against efgartigimod in serum
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
ADA: antidrug antibody(ies) |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Incidence of antibodies against rHuPH20 in plasma
Tidsramme: Up to 24 weeks (part A) + Up to 135 weeks
|
rHuPH20: recombinant human hyaluronidase PH20 |
Up to 24 weeks (part A) + Up to 135 weeks
|
|
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20. |
Up to 24 weeks (part A) + up to 135 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ARGX-113-25-GRD-3002
- 2025-524223-42-00 (Ctis)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .